E2F4 SIGNATURE FOR USE IN DIAGNOSING AND TREATING BREAST AND BLADDER CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jun 19, 2015
filing date -
Jul 30, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Methods for treating breast and bladder cancer patients based upon E2F4 regulatory activity as a predictor of relapse of a patient with estrogen receptor positive breast cancer and in bladder cancer stratification are provided. The methods involve determining gene expression profiles for substances linked to activity of E2F4 in cancer cells and tissue. Signature gene expression profiles are provided for identifying breast cancer samples and bladder cancer samples that would be responsive to certain therapies and also provide for prognosis based on these profiles.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully